Research Article: Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)
Introduction:
Retinopathy of Prematurity (ROP) continues to be a significant clinical concern in neonatal medicine, affecting the visual development and quality of life of premature infants worldwide. , The pathophysiology of ROP is intricately linked to aberrant vascular development within the developing retina of premature infants. , Insufficient vascularization during the early stages is followed by uncontrolled neovascularization in the later phases, culminating in potentially sight-threatening complications such as retinal…
Read more